{"organizations": [], "uuid": "1670cbb1213acf85a3f11e59fcb22a3442d4f367", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180530.html", "section_title": "Archive News &amp; Video for Wednesday, 30 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/therapeuticsmd-fda/fda-approves-therapeuticsmds-hormone-therapy-idUSL3N1T13XM", "country": "US", "domain_rank": 408, "title": "FDA approves TherapeuticsMD's hormone therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-30T18:08:00.000+03:00", "replies_count": 0, "uuid": "1670cbb1213acf85a3f11e59fcb22a3442d4f367"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/therapeuticsmd-fda/fda-approves-therapeuticsmds-hormone-therapy-idUSL3N1T13XM", "ord_in_thread": 0, "title": "FDA approves TherapeuticsMD's hormone therapy", "locations": [], "entities": {"persons": [{"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "therapeuticsmd inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 30 (Reuters) - The U.S. Food and Drug Administration approved TherapeuticsMD Inc’s hormone therapy for a painful condition triggered by menopause, the women’s health company said on Wednesday.\nIts estrogen treatment, Imvexxy, treats vulvar and vaginal atrophy, a condition caused by the loss of female hormone estrogen after menopause.\nSafety warnings on the drug’s label point to risks of endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia. (Reporting by Tamara Mathias in Bengaluru)\nOur Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and-landscape-tablet medium-wide-browser-and-larger above-phone portrait-tablet-and-above above-portrait-tablet landscape-tablet-and-above landscape-tablet-and-medium-wide-browser portrait-tablet-and-below landscape-tablet-and-below Apps Newsletters Advertise with Us Advertising Guidelines Cookies Terms of Use Privacy\nAll Quote: s delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.\n© 2018 Reuters. All Rights Reserved.", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-30T18:08:00.000+03:00", "crawled": "2018-05-31T16:19:42.034+03:00", "highlightTitle": ""}